Artificial intelligence is quietly reshaping the pharmaceutical industry and the financial upside could be enormous.
MyChesCo on MSN
FDA moves to cut costs for biosimilar drug development
WASHINGTON, D.C. — The U.S. Food and Drug Administration announced new draft guidance aimed at reducing the cost and ...
March 9 (Reuters) - The U.S. health regulator issued a draft guidance on Monday to help drugmakers develop cheaper versions ...
The FDA has proposed new rules to speed up the development of biosimilar drugs, aiming to reduce the costs of biologic ...
The Trump administration launched a drug pricing initiative offering immediate savings, but experts debated whether lower ...
The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate ...
Drug discovery is like molecular Tetris. Chemists snap atoms together, adjusting the pieces until everything fits, and ...
Competition to create new brand-name drugs is a key driver of innovation in the United States. Unfortunately, it also drives the relentless growth of healthcare spending. That’s because development of ...
Tired of seeing drug commercials on TV as health care costs continue to rise? So are advocates, who want to remove a state tax break for pharmaceutical ads, arguing that those funds would be better ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results